|
171 Beiträge ausgeblendet. |
|
Portola meldet Zahlen für Q1/19
investors.portola.com/news-releases/...-quarter-2019-financial
200 Mio. $ Offering geplant
investors.portola.com/...es-Proposed-Offering-of-Common-Stock
vorläufige Andexxa-Umsatzzahlen
Das die Umsätze von Andexxa im vierten Quartal 2019 unter den Umsätzen aus Q3/19 liegen ist überraschend und bedenklich.
"In the U.S., net revenues of Andexxa in the fourth quarter 2019 were approximately $24 million, which compares to net revenues of $14.0 million in the same period a year ago and $33.0 million in third quarter 2019."
investors.portola.com/...evenues-of-Approximately-111-Million
seekingalpha.com/news/...rtola-down-39-after-hours-on-weak-q4
(Kommentare Lesen!)
investors.portola.com/...esults-and-Provides-Corporate-Update
www.fool.com/investing/2020/01/10/...als-fell-as-much-as.aspx
Zahlen für 2019
"For the fiscal year 2020, Portola expects total R&D expenses to be between $105 million and $120 million, including stock-based compensation expenses of approximately $14 million. Portola expects total SG&A expenses to be between $235 million and $250 million, including stock-based compensation expenses of approximately $38 million."
investors.portola.com/...esults-and-Provides-Corporate-Update
Q-Zahlen und Corona-Virus Ängste
BMS und Pfizer steigen aus dem Entwicklungs-u. Kommerzialisierungspakt (anti-anticoagulants) in Japan aus
endpts.com/...-pfizer-pull-out-of-regional-deal-with-portola/
Alexion übernimmt Portola
"The transaction is expected to close in the third quarter of 2020."
investors.portola.com/2020-05-05-Alexion-to-Acquire-Portola
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
2 | 196 | Spekulation auf Turnaround | Costa Valeitis | Evidencebased | 25.04.21 03:36 |